A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma

• Status: Recruiting
• Trial end date: 2025-07-31

Summary

Primary Objective:

To determine the antitumor activity of SAR444245 in combination with other anticancer therapies.

Secondary Objectives:

• To confirm the dose and to assess the safety profile of SAR444245 when combined with other anticancer therapies.

• To assess other indicators of antitumor activity.

• To assess the pharmacokinetic (PK) profile of SAR444245 when given in combination with pembrolizumab.

• To assess the immunogenicity of SAR444245.

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Carboplatin; Paclitaxel; Pembrolizumab; Pemetrexed